India Set To Hear Sovaldi Patent Objections Case
This article was originally published in PharmAsia News
Executive Summary
India’s patent office has laid out a list of concerns on a pending Sovaldi application by Gilead Sciences – with the drug maker set to respond.
You may also be interested in...
Payers “Need A Bigger Boat” To Take On Pricing Like Sovaldi’s – Kaiser Permanente Exec
Kaiser Permanente’s Levine and Memorial Sloan Kettering’s Bach discuss approaches to restraining specialty drug costs at May 29 health care conference. CMS’ Tavenner suggests transparency and collaborating with industry on “appropriate use” can help manage costs of Gilead’s Sovaldi.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.